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Neuronal dysfunctionMetabolic syndrome (MetS) is a global epidemic, which involves a spectrum of metabolic disorders comprising
diabetes and obesity. The impact of MetS on the brain is becoming to be a concern, however, the poor under-
standing of mechanisms involved has limited the development of therapeutic strategies. We induced a MetS-
like condition by exposingmice to fructose feeding for 7 weeks. There was a dramatic deterioration in the capac-
ity of the hippocampus to sustain synaptic plasticity in the forms of long-term potentiation (LTP) and long-term
depression (LTD). Mice exposed to fructose showed a reduction in the number of contact zones and the size of
postsynaptic densities (PSDs) in the hippocampus, as well as a decrease in hippocampal neurogenesis. There
was an increase in lipid peroxidation likely associatedwith a deﬁciency in plasmamembrane excitability. Consis-
tent with an overall hippocampal dysfunction, there was a subsequent decrease in hippocampal dependent
learning and memory performance, i.e., spatial learning and episodic memory. Most of the pathological sequel
of MetS in the brain was reversed three month after discontinue fructose feeding. These results are novel to
show thatMetS triggers a cascade ofmolecular events, which disrupt hippocampal functional plasticity, and spe-
ciﬁc aspects of learning andmemory function. The overall information raises concerns about the risk imposed by
excessive fructose consumption on the pathology of neurological disorders.
Crown Copyright © 2015 Published by Elsevier B.V. All rights reserved.1. Introduction
In recent decades, there has been a progressive increase in the
incidence of metabolic diseases such as metabolic syndrome (MetS),
type II diabetes mellitus (T2DM) and obesity. T2DM affects approxi-
mately 15% of the global population, comprising over 400 million
patients worldwide [1]. The elevated consumption of fructose has
been identiﬁed as one of the major contributors to the epidemic of
MetS [2–6]. The burden of MetS is becoming even more alarming on
the light of recent reports suggesting that MetS disrupts brain functionl cerebro-spinal ﬂuid; CBF, cere-
ential; GCL, granule cell layer;
l; LTP, long-term potentiation;
WM, Morris Water Maze; PTX,
ar zone, T2DM type II diabetes
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r B.V. All rights reserved.and resilience to neurological disorders [7–10]. MetS increases the inci-
dence of cognitive disorders in aging and Alzheimer's disease (AD) [11,
12], and even in young individuals [13–15]. It has recently been report-
ed that a decrease in gray matter in several brain regions of patients
with T2DM, and the extent of this decrease are being proportional to
the duration of T2DM [16–19]. These results emphasize the existence
of a time period for the development of MetS on the brain, which can
be targeted for treatments to prevent the neurological sequel of MetS.
Unfortunately, the poor understanding of the cellular and molecular
mechanisms underlying the neuropathology of MetS has limited the
design of preventive therapies to copewith a potential epidemic of neu-
rological disorders [11].
The ability of neuronal circuits to store and process information is
one of the most fundamental pillars of brain function, and the loss of
this property conforms the pathology of most cognitive disorders. We
induced a condition like-MetS with a diet rich in fructose, a protocol
described before and proportional to the intake of fructose by humans
[20–22]. Accordingly, we have directed the current studies to under-
stand the impact of MetS on fundamental mechanisms underlying
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namely long-term potentiation (LTP) and depression (LTD). Our results
provide critical evidence for the impact of MetS on deteriorating neuro-
nal excitability in a brain region crucial for the processing of cognitive
information, i.e., hippocampus.We have extended our analysis to deter-
mine the impact ofMetS on adult neurogenesis as this process is consid-
ered a hallmark of the capacity of the brain for plasticity [23]. The
subgranular zone (SGZ) of the dentate gyrus displays a continuous gen-
eration of new neurons [24] that integrate into the pre-existing hippo-
campal circuitry [25]. Although some of the peripheral effects of MetS
may be treatable [11,26], the potential reversibility of the effects of
MetS on brain function is not understood. Accordingly, we sought to de-
terminewhether the deleterious consequences ofMetS on hippocampal
properties are reversible. Reported results are signiﬁcant to deﬁne a
mechanism by which fructose-induced MetS compromise the work of
neural circuits underlying cognitive function.
2. Methods
2.1. Animals and treatments
Weused two-month-old C57BL/6malemice, themicewere separat-
ed into two experimental groups (n = 19 per group) according to the
tap water that they received: a control group, which received normal
food and water, and a second group that received normal food and
water supplemented with 15% fructose by 8 weeks. The animals were
housed at the Animal House Facility of the Facultad de Ciencias
Biológicas, Pontiﬁcia Universidad Católica de Chile, according to the
Guide for the Care and Use of Laboratory Animals (NIH-USA Publication
86-23). After treatment the mice were used in the fellow order: 5 ani-
mals for electrophysiology experiments; 5 animals for the preparation
of synaptosomes, immunoblotting, and immunoﬂuorescence analysis;
9 animals for the cognitive test and the glucose tolerance test, and 3 an-
imals for hippocampal neurogenesis.
2.2. Biochemical analysis
MetS involves a conglomerate of pathological features including
obesity, insulin resistance, hypertension, high triglyceride levels, cardio-
vascular disease, and systemic inﬂammation [27,28]. Accordingly, we
measured several of these features in the animals exposed to fructose.
Blood was collected from the tail vein after 6 h of fasting, and then the
serum samples were obtained. Glucose levels weremeasured according
to the hexokinase/G-6-PDH method, using Architect Analyzer (Abbott
Laboratories, Abbott Park, IL), and insulin levels were measured via
chemiluminescence (Beckman Coulter); in both cases, the manufac-
turers' instructions were followed. The HOMA, an index of insulin resis-
tance [29,30], was calculated using the following formula: HOMA-R =
fasting glucose (mmol l−1) × fasting insulin (μIUml−1)/22.5. The levels
of triglycerides and cholesterol were assessed enzymatically using the
Architect c8000 analyzer (Abbott Laboratories, Abbott Park, IL).
2.3. Glucose tolerance test
After 30 days of special or standard diet, animals were fasted for 8 h
and then received an injection of glucose (1 g/kg b.w., i.p.). Blood glu-
cose was monitored for 90 min using a glucometer (Accu-Check,
Roche) on samples collected from the tip of the tail vein.
2.4. Cognitive task
The Morris Water Maze (MWM) task was performed as we have
previously described [31]. Brieﬂy, the mice were trained in a 1.2-
m-diameter circular pool (opaque water, 50 cm deep). The maxi-
mum trial duration was 60 s, and the animals were positioned on
the platform for 10 s at the end of each trial. To test episodic memory,each animal was trained to ﬁnd the platform per day for 4 days, using
a new platform location each day, as described previously [31]. The
large open ﬁeld (LOF) test was used to study locomotor and stress
behavior in our mouse model [32]. Each mouse was placed individu-
ally in the center of the open ﬁeld, and its behavior was tracked for a
20 min session. At the end of the session, the mice were returned to
their home cages. The parameters measured included: the total time
moving and the number of lines that crossed the center area of the
platform [33,34].
2.5. Electrophysiological recording
Hippocampal slices were prepared according to previously de-
scribed standard procedures [31]. Brieﬂy, transverse slices (350 μm) of
the dorsal hippocampus were cut under cold artiﬁcial cerebrospinal
ﬂuid and incubated in ACSF for 1 h at room temperature. In all experi-
ments, 10 μM picrotoxin (PTX) was included. Basal excitatory synaptic
transmission was measured using an input/output curve protocol,
which consisted of eight stimuli that ranged from 200 to 900 μA (with
a 10-s interval between stimuli). LTP was generated using TBS, which
consisted of 5 trains of the stimulus using an inter-train interval of
20 s. To generate LTD, we used LFS, consisting of 900 paired pulses at
1 Hz.
2.6. Preparation of synaptosomes
Crude synaptosomal fractions were prepared from the hippocam-
pus of the treated and control mice as described previously [35]. The
samples (50 μg of protein per sample) were subjected to SDS–PAGE,
followed by immunoblotting using the indicated antibodies. The
synaptosomal fraction from the hippocampus was examined using
a scanning electron microscope.
2.7. Immunoblotting
The synaptosomal fraction were homogenized in RIPA buffer
(50 mM, Tris–Cl, pH 7.5, 150 mM NaCl, 1% NP-40, 0,5% sodium
deoxycholate, and 1% SDS), supplemented with a protease inhibitor
cocktail (Sigma-Aldrich P8340) and phosphatase inhibitors (50 mM
NaF, 1 mM Na3VO4 and 30 μM Na4P207), using a potter homogenizator
and then passed sequentially through different caliber syringes. Protein
samples were centrifuged at 14,000 rpm at 4 °C twice for 15 min. Pro-
tein concentration was determined using the BCA Protein Assay Kit
(Pierce Biotechnology, Rockford, IL). 20 μg of synaptosomal fraction
were resolved by 10% SDS-PAGE and transferred to a PVDF membrane.
The reactions were followed by incubation with a primary antibody;
then a secondary anti-goat peroxidase conjugated antibody (Pierce)
was used and developed using an ECL kit (Western Lightning Plus ECL,
PerkinElmer). Primary antibodies used were mouse anti-GAPDH
(Sigma-Aldrich, St. Louis, MO), anti-GluR2 (Sigma-Aldrich, St. Louis,
MO), mouse anti-Synaptophysin (SYN) (Life Technologies, Carlsbad,
CA), anti-NMDAε1 (Sigma-Aldrich, St. Louis, MO) and mouse anti post-
synaptic density protein 95 (PSD-95).
2.8. Immunoﬂuorescence
Immunoﬂuorescence was performed as previously described [36].
The primary antibody used was mouse anti-4-HNE (Life Technologies,
Carlsbad, CA). The slices were subsequently mounted on slides using
mounting medium and analyzed using a Zeiss LSM 5 Pascal confocal
microscope. The images were analyzed using ImageJ software (NIH).
2.9. Analysis of hippocampal neurogenesis
After 4 weeks of control or fructose treatment, the animals were
injected i.p. with 100 mg kg − 1 5-Bromo-2′-deoxyuridine (BrdU,
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treatment animals were transcardially perfused with saline, followed
by 4% paraformaldehyde (PFA, Sigma-Aldrich) in PBS. Brains were re-
moved and sectioned on a cryostate in 12 sets of serial coronal slices
of 40 μm thickness; each set contained 5–7 slices covering the entire
length of the hippocampus. Immunodetection of BrdU and NeuN in tis-
sue sections was performed as described previously [37]. The primary
antibodies used were rat anti-BrdU (Sigma-Aldrich, St. Louis, MO) and
monoclonal anti-NeuN (Millipore). BrdU-positive cells were counted
using a ﬂuorescence microscope (Olympus BX51, Tokyo, Japan) as de-
scribed in [37]. For quantiﬁcation of net neurogenesis NeuN staining
in each BrdU-positive cell was detected using a confocal laser micro-
scope (Olympus FV1000) and z-plane sections of 1–2 sets of coronal
sections.
2.10. Studies of MetS remission
To study whether the effect of fructose are revertible we used three
groups of 15 animals, from which the ﬁrst group was treated with nor-
mal food plus water for 20 weeks. The second group was treated with
normal food plus 15% of fructose in water for 8 weeks, then the fructose
was replaced by plain water for another 12 weeks. In this group we
monitored the blood levels of glucose, insulin, total cholesterol, glucose
tolerance and triglycerides, and the HOMA index was calculated every
30 days. We observed a normalization of the blood parameters after 3
months, and this period was considered a critical time interval for the
remission of MetS (Table 2). The third group was treated during the
20 weeks with normal food and 15% of fructose supplemented into
the water. All the animals were sacriﬁced after 20 weeks: 5 animals
were used for electrophysiological recording, and 10 animals were
used for the cognitive studies and then blood was collected for physio-
logical measurements.
2.11. Statistical analysis
The results are presented as the means ± standard error. The data
were analyzed via one-way or two-way ANOVA followed by Bonferroni
post hoc analysis; *p ≤ 0.05 was considered signiﬁcant. Statistical analy-
sis was performed using Prism software (GraphPad).
3. Results
3.1. Establishment of MetS-like pathogenesis in mice
The protocol designed to induce MetS involved the addition of
15% fructose to the drinking water by 8 weeks (Fig. 1A). During the
treatment period, food and fructose/water intake were controlled.
We do not observed changes in the average of food intake by mice
(Fig. 1B). A difference in the fructose/water intake was observed be-
tween the two groups in the last three weeks. The group maintained
with fructose ingested more liquid compared with the control group
(Fig. 1C).
We also controlled the average weight of mice and we observed an
increase in the weight of animals supplemented with 15% of fructose
in the last twoweeks (Fig. 1D). Liverweight provides an indirect assess-
ment of liver function, and fructose treatment induced a 41.5± 9.3% in-
crease in liver weight, normalized to the body weight of both groups
(Fig. 1D).
To conﬁrm the induction of MetS, we measured several blood pa-
rameters including the glucose tolerance test. We observed that the
group supplemented with fructose present a decrease in the capacity
of regulate the glucose levels after the injection of glucose (Fig. 1F).
Also we observed other parameters used in the diagnosis of MetS in-
cluding the blood levels of glucose, insulin, total cholesterol and triglyc-
erides, and calculated the HOMA ratio. Fructose treatment increased
glucose levels (37.7±7%), insulin levels (178±29%), cholesterol levels(54.5 ± 12.2%), and triglyceride levels (69.2 ± 11.3%), and the HOMA
index was increased 3-fold in the fructose treated group (Table 1) [38].
3.2. MetS impairs spatial memory performance
Spatial memory was assessed using the Morris water maze (MWM)
paradigm, which was performed in a blinded manner. For the ﬁrst four
days, the mice in both groups took approximately the same length of
time to ﬁnd the platform at the end of the test (latency time); however,
by day 5, the MetS group took longer time to locate the platform com-
pared with the control group (40 ± 6 s and 21 ± 3 s, respectively).
The trend continued up to day 10, which suggests a decline in the learn-
ing andmemory abilities of theMetS group (Fig. 2A). The increase in la-
tency timewas associatedwith a longer swimming distance in theMetS
group (Fig. 2B). No difference in swimming speed was observed be-
tween the two groups; this rules out the possibility that the increased
latency time was a result of muscular failure or visual deﬁciency
(Fig. 2C). On the ﬁnal day of the test, the platform was removed and
the time that the animals spent in each of the four quadrants of the
pool was recorded: northwest (NW), northeast (NE), southwest (SW)
and southeast (SE). In the absence of a platform, the control group
spentmore time (25±3 s) in thequadrantwhere the platformhad pre-
viously been located (NE) than the MetS group (15 ± 2 s), while the
MetS group had no preference for any particular quadrant (Fig. 2D).
The LOF test was used to evaluate general locomotor activity and ex-
ploration [39]. We evaluated parameters related to spontaneous behav-
ior in mice including the time of moving and the number of lines that
crossed the center. No signiﬁcant difference was observed between
the two groups, which suggest MetS does not inﬂuence the general sta-
tus of animals (Fig. 2E and F).
A modiﬁed spatial-memory paradigm to assess episodic memory or
memory ﬂexibility was used. The assessment of memory ﬂexibility pro-
vides a sensitive indication of hippocampal function since the position
of the hidden platform is changed every day. The MetS group required
signiﬁcantly more trials to complete the test compared with the control
group (10 and 6, respectively) starting the ﬁrst day and maintained for
all 5 days of the test (Fig. 2G).
3.3. MetS impairs hippocampal synaptic plasticity
We examined the effects of MetS on hippocampal synaptic plasticity
to elucidate a potential mechanism underlying the behavioral results.
Synaptic integrity was assessed using electrophysiological recordings
for input–output analysis [31]. The ﬁeld excitatory postsynaptic poten-
tial (fEPSP) was not altered in theMetS group (Fig. 3A and B); however,
the ﬁber volley, an indicator of axonal excitability, was decreased in
amplitude by 70 ± 19% using a stimulus strength of 1000 μA (Fig. 3C
and D), which indicates an alteration in synaptic transmission at the
presynaptic level. We measured LTP and LTD, which reﬂect persistent
changes in synaptic connectivity underlying learning andmemory func-
tions. A set of protocols for theta burst stimulation (TBS) and low-
frequency stimulation (LFS) was used to induce LTP and LTD, respec-
tively. Notably, it was not possible to induce robust LTP in the MetS
mice, who displayed a maximum of 1.33 ± 0.12 mV compared with a
maximum 1.95 ± 0.12 mV in the control group. Furthermore, in the
control group, the induction and maintenance of LTP persisted for at
least 60 min of recording (1.67 ± 0.11 mV in the control group and
1.1 ± 0.14 mV in the MetS group; Fig. 3E). In contrast to LTP, LTD indi-
cates a reduction in synaptic strength [40]. It was almost impossible to
induce LTD in the fructose-treated animals (0.67 ± 0.054 mV) relative
to the control group (1.17±0.13mV) at 60min (Fig. 3F). These changes
in LTP and LTD suggest that MetS leads to deregulation of hippocampal
synaptic transmission and plasticity. We also determined the effects
of MetS on synaptic structure by examining the synaptosomal frac-
tion from the hippocampus using electron microscopy (Fig. 4A). We
found a decrease in the number of synaptic contacts from 27 ± 3 per
Fig. 1. Establishment of like-MetS condition. (A) Representative model of the induction of MetS in mice. (B) Average food intake during the 8 weeks of treatment. (C) Water of fructose
intake during the treatment time. (D) Averageweight of control and treated group. (E) Liver weight in the treated animals (F) Glucose tolerance test by 90min after glucose injection. The
values are expressed as the means ± SEM of n, *p b 0.05 based on ANOVA (one-way) followed by Bonferroni post hoc analysis.
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(Fig. 4B).We also observed a decrease in thewidth of postsynaptic den-
sity (PSD, n= 5) from 68± 9 nm in the control group to 33± 13 nm in
the fructose treated group (Fig. 4C). We did not observe any changes inTable 1
Blood values after treatment with fructose 15% by 8 weeks.
Glucose
(mg/dL)
Insulin
(μIU/mL)
HOMA index Cholesterol
(mg/dL)
Triglycerides
(mg/dL)
Control 98 ± 6 0.93 ± 0.20 0.23 ± 0.06 121 ± 15 78 ± 15
Fructose 135 ± 10* 2.59 ± 0.15** 0.86 ± 0.06* 187 ± 13* 132 ± 12*
The values are expressed as the means ± SEM of n: 9 animals per group. *p b 0.05 and
**p b 0.01 based on ANOVA (one-way) followed by Bonferroni post hoc analysis.the number of vesicles or the length of the PSD regions (Fig. 4D and E).
In the synaptosomal fractions, we performed western blot for several
pre- and post-synaptic proteins and observed a signiﬁcant decrease in
the expression of the glutamate receptor subunits NMDAε1 and GluR2
(Fig. 4F and G). Together, these results provide clear and novel evidence
for the impact of MetS on the structural and molecular composition of
hippocampal synapses.
3.4. MetS decreases hippocampal neurogenesis
We examined the effects of MetS on hippocampal neurogenesis as
the generation of new neurons contributes to neural plasticity and
memory [41–43]. First, we evaluated the effect of MetS on cell prolifer-
ation in the SGZ by incorporation of the nucleotide analog BrdU. A
Fig. 2. The induction ofMetS leads to a decrease in cognitive performance. (A) The time required to ﬁnd the hidden platform (latency time)was determined for both groups. (B) Speed of
swim of both groups during theMWM test. (C) Swimming path during theMWM test by group. (D) The time spent in each quadrant in the absence of the platform. (E and F) In the large
open ﬁeldwemeasured the number of lines crossing the center and the time ofmoving. (G) The performance of both groups on thememory-ﬂexibility taskwas analyzed by assessing the
number of trials to meet the criteria. The values are expressed as the means ± SEM of n animals per group and were analyzed via ANOVA (one-way) followed by Bonferroni post hoc
analysis.
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served in the granule cell layer (GCL) of mice treated with fructose. To
evaluate the generation of new neurons, the expression of the mature
neuronal marker NeuN in each BrdU-positive cell was evaluated in the
hippocampus 4 weeks after BrdU injection (Fig. 5A). There was a signif-
icant decrease (50%) in the total number of newborn granule cells (total
number of BrdU+/NeuN+ cells in the entire GCL) in the fructose-treated
animals (Fig. 5B and C). These data show that MetS decreases adult hip-
pocampal neurogenesis.3.5. MetS increases oxidative stress
Oxidative metabolism is directly associated with the integrity of the
plasma membrane and is a factor in almost all neurodegenerative
diseases, as well as aging [44]. To determine whether MetS affects oxi-
dative metabolism, we measured the levels of 4-HNE, an aldehyde
product of lipid peroxidation that serves as a marker of plasma mem-
brane damage [45]. Plasmamembrane integrity is essential for neuronal
signaling. Notably, the intensity of 4-HNE immunoﬂuorescence was
Fig. 3.MetS reduces the excitability of the hippocampus. (A–D) First, synaptic integrity was evaluated via input–output analysis of the electrophysiological recordings. (E) LTP was mea-
sured in thehippocampal slices of themice in both groups (drinkingwaterwith orwithout supplemental fructose). (F) LTDwasdetermined inboth groups. The values are expressed as the
means ± SEM of n animals per group. *p b 0.05 based on ANOVA (one-way) followed by Bonferroni post hoc analysis.
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and CA3 (2- and 3-fold, respectively) and displayed an increasing
trend in the dentate gyrus (2-fold) of the MetS group compared
with the control group (Fig. 5D and E). These results corroborate
the effects of MetS on lipid peroxidation with potential repercussion
on membrane function.
3.6. Remission of MetS is associated with recovery of hippocampal function
To study if the effects of fructose are reversible, after fructose
treatment, we prepare 3 groups of mice (Fig. 6A). In each group we
monitored the blood levels of glucose, insulin, total cholesterol, and
triglycerides and the HOMA index every 30 days. We observed a nor-
malization of the blood parameters after 3 months, and this periodwas considered a critical time interval for the remission of MetS
(Table 2).
We observed that the control (group 1) and remission group (group
2) showed a similar capacity of regulate glucose levels after injection of
glucose. However the group treated with fructose by 20 weeks showed
a several deregulation in the glucose levels control (Fig. 6B).
The remission group exhibited normalized memory performance in
the MWM test, as evidenced by spending a time in the platform quad-
rant nearby to control values. However, the group treated with fructose
by 20weeks showed a increase in the latency time and a decrease in the
capacity of remember the localization of the platform (Fig. 6C and D).
Likewise the remission of MetS resulted in normalization of synaptic
transmission and LTP induction such that no differences were observed
between the remission and control groups (Fig. 6D).
Fig. 4.MetS affects the synaptic structure of the hippocampus. (A–E) Electron microscopy of synaptosomal fractions and quantiﬁcation of several characteristics of the pre- and post-syn-
aptic regions (red arrows). (F–G)The induction ofMetS triggered a decrease in the levels of pre- andpost-synaptic proteins. Scale: 200nm. The values are expressed as themeans±SEMof
n animals per group. *p b 0.05 based on ANOVA (one-way) followed by Bonferroni post hoc analysis.
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An increasing number of clinical reports depict the impact of altered
systemic metabolism on the incidence of a large variety of neurological
disorders. We present new mechanistic evidence for the disruptive
effects of fructose-induced MetS on crucial aspects of neuronal excit-
ability underlying brain function and plasticity. Animals exposed to
fructose lost their ability to sustain hippocampal LTP and LTD, showed
a reduction in density and size of active zones at synapses, and reducedthe generation of newneurons in the hippocampus. All of these changes
are congruent with a reduction in learning and memory performance,
and the prospect of elevated vulnerability to neurological disorders.
These results are particularly signiﬁcant on the context of the epidemic
of metabolic disorders such as obesity and diabetes [46,47]. The effects
of fructose-induced MetS on hippocampal plasticity were partially
reversible after ceasing fructose consumption, which suggests the exis-
tence of a window of opportunity for the application of preventive
programs.
Fig. 5.MetS reduces the generation of new neurons in the adult hippocampus and increase the levels of oxidative stress. (A) Representative immunoﬂuorescence staining for BrdU and
NeuN. The inset shows a higher magniﬁcation of BrdU-positive cells that are also positive for NeuN. The arrows indicate BrdU+ cells. Scale bar: 50 μm (original magniﬁcation 20×).
(B–C) The total number of BrdU+ and BrdU+/NeuN+ cells in the GCL was determined. (D–E) Quantiﬁcation of the immunoﬂuorescence signal normalized to that under the control con-
ditions. 4-HNE, red; nuclear stain Hoechst, blue. The values are expressed as the means ± SEM of n animals per group. *p b 0.05 and **p b 0.01 based on ANOVA (one-way) followed by
Bonferroni post hoc analysis. Scale bar: 100 μm.
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Fig. 6.MetS remission enabled amelioration of speciﬁc aspects of hippocampal deterioration. (A).We used three groups of animals: control with normal diet, fructose-treated for 8weeks
followed by fructose removal for 12weeks, fructose-treated for 20weeks. (B) Glucose tolerance test was performed to assess insulin resistance. (C) Behavioral performance on theMWM
task was normal after remission and no difference was observed compared to control animals. We observed a signiﬁcant decrease in the cognitive performance in the group treatedwith
fructose for 20 weeks. (D) In the absence of the platform, we did not observe any differences between the remised and control groups. (E and F) Recovery of LTP depression after MetS
remission. The values were expressed as the means ± SEM. *p b 0.05 and **p b 0.01 based on ANOVA (one-way) followed by Bonferroni post hoc analysis.
2387P. Cisternas et al. / Biochimica et Biophysica Acta 1852 (2015) 2379–2390In our model we observed that the treatment with fructose induce
changes in several blood markers commonly used for the diagnosis of
MetS in humans, including insulin resistance, blood glucose, triglycer-
ides and cholesterol, and obesity. We obtained similar results to thoseTable 2
Blood values after remission time.
Glucose
(mg/dL)
Insulin
(μIU/mL)
HOMA
index
Cholesterol
(mg/dL)
Triglycerides
(mg/dL)
Control 103 ± 4 1.1 ± 0.4 0.25 ± 0.08 112 ± 14 85 ± 12
Remission 115 ± 9 0.99 ± 0.15 0.28 ± 0.04 125 ± 13 102 ± 14*
Chronic
fructose
155 ± 10* 2.86 ± 0.21** 0.93 ± 0.08* 211 ± 19* 159 ± 18*
The values are expressed as themeans±SEMof n: 10 animals per group. *p b 0.05 and **p
b 0.01 based on ANOVA (one-way) followed by Bonferroni post hoc analysis.previously reported, suggesting that our treatment induces a like-
MetS pathology [11,21,26,48].
4.1. Fructose-induced MetS reduces functional and structural synaptic
plasticity
Our results show that fructose-induced MetS affects the long-term
modulation of basal synaptic transmission and associated axonal
excitability of hippocampal synapses [49]. Adaptations in hippocampal
synaptic plasticity, such as LTP and LTD, underlie changes in spatial
learning and memory processing [50]. The disruption in the balance
between LTP and LTD in the MetS group is likely a primary event for
the observed failure in learning andmemory functions [51]. It is notable
that these events were detected in the hippocampus, the locus of asso-
ciative memory [52], which is heavily compromised during aging and
AD. We also observed fewer active zones and smaller PSD regions in
2388 P. Cisternas et al. / Biochimica et Biophysica Acta 1852 (2015) 2379–2390the animals exposed to fructose, which harmonizewith the dysfunction
in LTP and cognition. Taken together, these results suggest that MetS
reduces neuronal excitability and hippocampal function,which are nec-
essary to support learning and memory processing.
Hippocampal neurogenesis is important for maintaining cognitive
performance in adult mice and is considered a symbol of hippocampal
plasticity [41–43]. According to our results, MetS reduced neurogenesis
in the SGZ of the dentate gyrus, where newborn neurons integrate into
the pre-existing hippocampal circuitry [25] and are involved with LTP
and LTD [42,43]. Immature newborn neurons display greater excitabili-
ty thanmature neurons mostly due to reduced inhibition by GABA [53].
These immature neurons appear to contribute to LTP, as suggested by
ﬁndings that blocking neurogenesis prevents the expression of LTP
[41]. In addition, adult-born neurons are involved in certain aspects of
hippocampus-dependent learning and memory, such as spatial memo-
ry, pattern separation and contextual fear conditioning [54,55]. A
decrease in neurogenesis is a feature in the pathology of several neuro-
logical disorders [56,57]. Reminiscent of the altered levels of insulin in
the MetS condition, it has been reported that insulin plays a central
role in the formation of new neurons in the brain [58]. Therefore, it is
possible thatMetS could impact neural plasticity and cognitive function
by altering neurogenesis. MetS could also inﬂuence neuronal plasticity
and cognition by altering the function of the plasma membrane.
Oxidative metabolism is directly associated with the integrity of the
plasma membrane and is a factor in almost all neurodegenerative dis-
eases, as well as in aging [44]. We measured the levels of 4-HNE, an
aldehyde product of lipid peroxidation that serves as amarker of plasma
membrane damage [45]. The plasmamembrane is crucial for supporting
neuronal excitability and signaling, which depend largely on the integ-
rity of its phospholipid composition. The oxidative marker 4-HNE is an
end-product of lipid peroxidation [59], which increase in the fructose
treated mice could be indicative of impaired membrane-related neuro-
nal excitability. Lipid peroxidation affects several processes associated
with synaptic activity, including ion uptake, ion-channel activity, glu-
cose metabolism, glutamate uptake and Na+/K+- and Ca2+-ATPase
activity [60].4.2. Fructose-induced MetS reduces learning and memory function
We found that MetS caused a disruption of spatial learning, which is
a sequel of Alzheimer's and Parkinson's diseases [61,62]. Remarkably,
AD might represent a “type 3 diabetes” based on deregulated insulin
and glucose metabolism that are components of its pathology [63–65].
On the episodic memory tests, which require the mice to learn and
memorize daily alterations in the platform location, the MetS group re-
quired more attempts to locate the hidden platform than the control
group. These cognitive deﬁcits were likely not a result of visual or mus-
cular deﬁciencies because the swimming speed of theMetSmice did not
differ from that of the controlmice. These results are relevant to humans
because this type of memory is essential for coping with daily routines,
such as remembering speciﬁc series of events within contexts. One of
the most relevant questions from a public health standpoint is whether
the effects ofMetS on the brain are reversible.We assessed this possibil-
ity by removing fructose from the diet after the establishment of the
MetS condition. We monitored the blood glucose levels once a month
and found that the levels of glucose tolerancewere similar to the control
levels 3 months after terminating the fructose-containing diet. Remark-
ably, spatial-learning performance was nearly completely normalized.
In addition, there was complete recovery from LTP. However, other
properties did not recover, such as LTD, emphasizing the strong impact
of MetS on the brain. Conversely, we also set a groupwith a chronic ex-
position to fructose; this groups present a several alteration in the blood
parameters as also in the cognitive performance. These data are impor-
tant for identifying speciﬁc aspects of MetS that may serve as targets of
therapeutic strategies to reduce its effects on the brain. These ﬁndings,upon further validation in humans, are critical for the development of
public health policies.
4.3. How fructose affects the brain
The animals exposed to high fructose exhibited several hallmarks of
MetS as deﬁned in humans by increases in weight, dyslipidemia,
impaired glucose tolerance, and insulin levels. In particular, our results
revealed a signiﬁcant increase in liver weight, which is consistent with
the effects of fructose on lipid deposition and the sequel of fatty liver
disease [11,38].
MetS in humanshas been associatedwith an increased risk of neuro-
logical disorders [66,67], however, the mechanisms by which MetS
impairs cognitive processing are poorly understood. Fructose could in-
ﬂuence the brain by elevating various peripheral parameters of MetS
such as increased adiposity, insulin, and triglycerides [11,21,68], and
some of the associated metabolites could reach the brain. An emerging
line of evidence indicates that fructose could inﬂuence brain function di-
rectly, i.e., neuronal cells are able to metabolize fructose uptaken from
the extracellular medium [69]. Administration of 20% of fructose in-
duces an increase in the glucose transporter 5 (GLUT5) in glial cells in
the hippocampus and cortex in rats. GLUT5 is the main transporter of
fructose into the brain and likely important for neuronal function
[70–72]. Intraventricular administration of fructose provokes feeding
in rodents and suggests a direct action of fructose on hypothalamic
function in appetite. The administration of fructose lead to a reduction
in cerebral blood ﬂow (CBF) in the thalamus, hippocampus, posterior
cingulate cortex, and visual cortex [73]. A reduction in CBF has been as-
sociated with alterations in CA1 hippocampal cells including reductions
in dendritic arborization and spine density [74].
5. Conclusions
MetS, obesity and diabetes have become worldwide epidemics that
affect patients of all ages and result in high health care costs [75]. Our
results indicate that fructose induced MetS affects speciﬁc aspects of
neuronal and synaptic plasticity, and raises concerns about the risk
imposed of MetS for the pathogenesis of disorders affecting cognitive
abilities such as AD [11] and depression/anxiety [76]. Given the current
lack of effective pharmacological approaches to treat these disorders,
the most effective therapy is prevention [77], and our results provide
some evidence for the reversibility of the neural pathogenesis related
to the MetS. The results of this study demonstrate that MetS disrupts
the function of neuronal circuits involved in cognitive processing
while MetS remission normalizes these alterations. These results are
signiﬁcant to deﬁne a targetable mechanism to reduce the risk posed
by altered metabolism on neurological disorders.
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